A Phase 3 interventional study of Cediranib and FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer, sponsored by AstraZeneca. Completed at 91 sites in 15 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2016-12-28.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing Folfox protocol in Colorectal Neoplasms — 14 open to participants now, 17 under way, 3 of them phase 3. Folfox protocol · Colorectal Neoplasms.
Among the 37 studies testing Folfox protocol in Colorectal Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2006, is one of 7 in phase 3, and was the 3rd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →14 of the 37 studies testing Folfox protocol in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Maimónides Biomedical Research Institute of Córdoba · Sites in Spain
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+
Shanghai Pudong Hospital · Sites in China
Ages 18–75
UNICANCER · Sites in France
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 24 · Phase 3 8
First in 2004; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,254 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 102 across the 37 interventional studies. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 37 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
29 studies in Colorectal Neoplasms by AstraZeneca: 2 open now, 8 under way, none of them phase 3. Of 19 finished, 7 (37%) have results posted.
Among the 29 studies in Colorectal Neoplasms by AstraZeneca, this one is the 2nd largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2006, is the only one in phase 3, and was the 9th registered.
AstraZeneca’s Colorectal Neoplasms studies by the year they started, since 2003.
5 of the studies testing Folfox protocol in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06475352UNICANCERDose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme | 2027-04 |
| NCT06106308Cardiff OncologyStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | 2027-04-16 |
| NCT07106034Shanghai Pudong HospitalStandard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial | 2027-07-31 |
| NCT06991465Neil KopekOrgan Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA) | 2027-09 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies testing Folfox protocol in Colorectal Neoplasms, from their registry updates:
Among AstraZeneca’s 29 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated metastatic colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FOLFOX + placebo Cediranib
Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) · Drug: Cediranib Placebo
Xelox + placebo Cediranib
Drug: XELOX (Capecitabine and Oxaliplatin) · Drug: Cediranib Placebo
FOLFOX + Cediranib
Drug: Cediranib · Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
XELOX + Cediranib
Drug: Cediranib · Drug: XELOX (Capecitabine and Oxaliplatin)
oral tablet
Also known as: AZD2171, RECENTIN™
intravenous infusion
Also known as: Other Names:, 5-FU, Drug: Leucovorin (in FOLFOX), intravenous infusion, Drug: Oxaliplatin (in FOLFOX), Eloxatin®
Drug page: Xelox
intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)
Also known as: Xeloda® + Eloxatin®
oral tablet
Progression-free Survival
RECIST criteria defined as follows: Target lesions Complete Response (CR) Disappearance of all target lesions Partial Response (PR) At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non-target lesions Complete Response (CR) Disappearance of all non-target lesions Non-Complete Response (non-CR/Non- Progression \[non-PD\]) Persistence of one or more non-target lesion or/and maintenance of tumour marker level above the normal limits. Progression (PD) Unequivocal progression of existing nontarget lesions.
Time frame: RECIST assessed at baseline every 6 weeks through to week 24 and 12 week thereafter through to progression or data cut off date of 21/03/10 whichever was earliest.
Overall Survival
Number of months from randomisation to the date of death from any cause
Time frame: Baseline through to date of death upto and including data cut off date of 21/03/10
Overall Response Rate
Objective tumour response(defined as a confirmed response of CR or PR).The definition for a confirmed response was met when an initial RECIST response of PR/CR was confirmed at the next scheduled visit as a PR/CR according to an evaluable assessment.Intervening assessments of non-evaluable or stable disease were allowable as long as the initial RECIST response was confirmed.RECIST criteria defined as follows: Target lesions Complete Response(CR)Disappearance of all target lesions Partial Response (PR).At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.Non-target lesions Complete Response (CR) Disappearance of all non-target lesi
Time frame: Baseline through to date of death upto and including data cut off date of 21/03/10
Best Percentage Change in Tumour Size
Maximum percentage reduction or minimum percentage increase in tumour size where size is the sum of the longest diameters of the target lesions
Time frame: Baseline through to date of death upto and including data cut off date of 21/03/10
Duration of Response
Based on RECIST measurements taken throughout the study and best objective tumour response at the defined analysis cut-off point. Measured from the time the criteria for CR/PR are first met (whichever is recorded first) until the patient progresses or dies.
Time frame: Treatment period from initial response up until data cut-off date of 21/03/10
Rate of Resection of Liver Metastases
Number of patients undergoing liver resection, based on patients with liver disease at baseline
Time frame: Post-randomisation until end of study
Time to Wound Healing Complications
Number of days from post-randomisation surgery until wound healing complications
Time frame: Post-randomisation until end of study
Randomised=full analysis set: Cediranib 20mg=502, Placebo=358; Safety set: Cediranib 20mg=500, Cediranib 30mg=214, Placebo=358
| Milestone | Cediranib 20 mg/Day | Cediranib 30 mg/Day | Placebo |
|---|---|---|---|
| Started | 502 | 216 | 358 |
| Completed | 189 | 58 | 106 |
| Not completed | 313 | 158 | 252 |
| Withdrew: Death | 289 | 141 | 234 |
| Withdrew: Lost to follow-up | 2 | 1 | 5 |
| Withdrew: Withdrawal by subject | 19 | 15 | 12 |
| Withdrew: Incorrect enrolment/eligib not fulfilled | 1 | 0 | 1 |
| Withdrew: Severe non-compliance with protocol | 2 | 1 | 0 |
RECIST criteria defined as follows: Target lesions Complete Response (CR) Disappearance of all target lesions Partial Response (PR) At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non-target lesions Complete Response (CR) Disappearance of all non-target lesions Non-Complete Response (non-CR/Non- Progression \[non-PD\]) Persistence of one or more non-target lesion or/and maintenance of tumour marker level above the normal limits. Progression (PD) Unequivocal progression of existing nontarget lesions.
| Months | Cediranib 20 mg | Placebo |
|---|---|---|
| Progression-free Survival | 8.6 (5.5 to 12.1) | 8.2 (4.1 to 11.1) |
Number of months from randomisation to the date of death from any cause
| Months | Cediranib 20 mg | Placebo |
|---|---|---|
| Overall Survival | 19.7 (11.0 to 36.1) | 18.9 (11.0 to 28.9) |
Objective tumour response(defined as a confirmed response of CR or PR).The definition for a confirmed response was met when an initial RECIST response of PR/CR was confirmed at the next scheduled visit as a PR/CR according to an evaluable assessment.Intervening assessments of non-evaluable or stable disease were allowable as long as the initial RECIST response was confirmed.RECIST criteria defined as follows: Target lesions Complete Response(CR)Disappearance of all target lesions Partial Response (PR).At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.Non-target lesions Complete Response (CR) Disappearance of all non-target lesi
| Participants | Cediranib 20 mg | Placebo |
|---|---|---|
| Overall Response Rate | 254 | 178 |
Maximum percentage reduction or minimum percentage increase in tumour size where size is the sum of the longest diameters of the target lesions
| Percentage [change in tumour size (mm) ] | Cediranib 20 mg | Placebo |
|---|---|---|
| Best Percentage Change in Tumour Size | -42.49 ± 28.139 | -40.61 ± 31.992 |
Based on RECIST measurements taken throughout the study and best objective tumour response at the defined analysis cut-off point. Measured from the time the criteria for CR/PR are first met (whichever is recorded first) until the patient progresses or dies.
| Months | Cediranib 20 mg | Placebo |
|---|---|---|
| Duration of Response | 8.5 (5.9 to 12.7) | 6.9 (4.8 to 11.0) |
Number of patients undergoing liver resection, based on patients with liver disease at baseline
| Participants | Cediranib 20 mg | Placebo |
|---|---|---|
| Rate of Resection of Liver Metastases | 21 | 17 |
Number of days from post-randomisation surgery until wound healing complications
| Days | Cediranib 20 mg | Placebo |
|---|---|---|
| Time to Wound Healing Complications | 18 (1 to 93) | 18 (0 to 114) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cediranib 30mg | — | 94/214 (43.9%) | 209/214 (97.7%) |
| Cediranib 20mg | — | 204/500 (40.8%) | 485/500 (97%) |
| Placebo | — | 105/358 (29.3%) | 341/358 (95.3%) |
| Event | Cediranib 30mg | Cediranib 20mg | Placebo |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/214 | 34/500 | 11/358 |
| DehydrationMetabolism and nutrition disorders | 8/214 | 14/500 | 7/358 |
| HypertensionVascular disorders | 8/214 | 6/500 | 2/358 |
| VomitingGastrointestinal disorders | 5/214 | 7/500 | 8/358 |
| Renal FailureRenal and urinary disorders | 5/214 | 3/500 | 0/358 |
| PneumoniaInfections and infestations | 3/214 | 7/500 | 8/358 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/214 | 11/500 | 7/358 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 4/214 | 10/500 | 4/358 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 4/214 | 4/500 | 3/358 |
| Intestinal ObstructionGastrointestinal disorders | 3/214 | 8/500 | 4/358 |
| Event | Cediranib 30mg | Cediranib 20mg | Placebo |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 147/214 | 346/500 | 165/358 |
| NauseaGastrointestinal disorders | 92/214 | 256/500 | 169/358 |
| VomitingGastrointestinal disorders | 83/214 | 230/500 | 126/358 |
| Decreased AppetiteMetabolism and nutrition disorders | 92/214 | 229/500 | 125/358 |
| HypertensionVascular disorders | 96/214 | 226/500 | 41/358 |
| FatigueGeneral disorders | 80/214 | 200/500 | 104/358 |
| Peripheral Sensory NeuropathyNervous system disorders | 45/214 | 141/500 | 89/358 |
| ThrombocytopeniaBlood and lymphatic system disorders | 56/214 | 139/500 | 84/358 |
| NeutropeniaBlood and lymphatic system disorders | 49/214 | 138/500 | 75/358 |
| StomatitisGastrointestinal disorders | 59/214 | 118/500 | 48/358 |
| Age, Continuous(years) | Cediranib 20 mg | Placebo | Cediranib 30 mg | Total |
|---|---|---|---|---|
| Mean | 57.8 ± 11.14 | 57.2 ± 11.63 | 59.4 ± 10.69 | 57.6 ± 11.34 |
| Gender(Participants) | Cediranib 20 mg | Placebo | Cediranib 30 mg | Total |
|---|---|---|---|---|
| Female | 203 | 146 | 93 | 442 |
| Male | 299 | 212 | 123 | 634 |
The record gives a start of Nov 2006, a primary completion of Mar 2010 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 2 years 7 months after primary completion. A results delay was requested in Apr 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cediranib · Folfox protocol · Xelox